Petauri Strengthens Medical Communications with Emotive Acquisition

Petauri Expands Global Medical Communications Through Acquisition of Emotive

In a move that solidifies its position within the pharmaceutical services sector, Petauri has announced its acquisition of Emotive, a respected medical communications agency known for its innovative approach to complex healthcare challenges. This significant acquisition, revealed on November 10, 2026, will bolster Petauri Advance, the company’s collective of medical communications, by adding pivotal global resources and profound expertise in scientific and creative strategies.

The Vision Behind the Acquisition

Petauri’s CEO, Dan Renick, emphasized the necessity for partners who can seamlessly interpret the intricate science of modern therapies for stakeholders influencing patient care. As the landscape of healthcare evolves, with therapies becoming increasingly sophisticated, the demand for communicative clarity grows.

“Emotive skillfully merges scientific precision with creative innovation, ensuring that lifesaving treatments reach those who need them most,” Renick commented. This partnership reflects a shared commitment to enhance communication in the healthcare sector, turning complex scientific concepts into comprehensible narratives.

Founded in 2013, Emotive has carved out a niche in the realm of medical communications, excelling particularly in areas such as neuroscience, immunology, and oncology. The agency boasts a reputation for tackling some of healthcare's most intricate challenges, which will now amplify Petauri’s ability to provide integrated solutions that are not only strategic but also creatively appealing.

Expanding Petauri Advance

With the incorporation of Emotive, Petauri Advance will now unify several renowned strategic medical agencies including DRIVE, PROPEL, and MOMENTUM, enhancing its capability to provide comprehensive medical communication services. This integration allows Petauri to better cater to its client base by offering services that span strategic planning, disease education, promotional communications, and more.

Chris Edmonds, the founder and CEO of Emotive, echoed the sentiments of excitement over the merger. He stated, “Joining Petauri is an exhilarating chapter for Emotive, where we can enrich our value to clients while remaining the reliable partners they’ve come to trust.” He is set to transition into an Executive Advisor role, guiding the firm’s ongoing commitment to impactful communications.

Lisa Hefner, Group President of Petauri Advance, noted the alignment of core values and visions between the two companies as critical for success. “The complementary expertise within our teams allows us to deliver earlier interventions that significantly enhance patient outcomes,” Hendner explained, signaling a bright future for healthcare communications post-acquisition.

A Step Towards Innovation

This acquisition marks Petauri’s continued growth trajectory, which has seen the company expand to over 600 professionals focused on market access and scientific communications. In partnership with numerous healthcare clients, Petauri aims to underscore the clinical and economic value of innovative medical treatments, thus speeding their accessibility to those who need them.

Petauri is head-quartered in Nashville, Tennessee, and has rapidly established itself as a pivotal player in the pharmaceutical landscape since its foundation in 2023. The firm operates through various units, including Petauri Advance and Petauri Advisors, while leveraging significant investments from Oak Hill Capital for ongoing innovation in pharmaceutical services.

This merger with Emotive is not just about expansion; it is a strategic alliance that represents the future of medical communications. By integrating their efforts, both companies aim to elevate the standards of patient care through improved understanding and delivery of critical healthcare information.

For more insights about Petauri and its ongoing initiatives, visit www.petauri.com.